<DOC>
	<DOCNO>NCT01466725</DOCNO>
	<brief_summary>The purpose study ass CC-930 safe tolerable treat subject Discoid Lupus Erythematosus . Pharmacokinetic pharmacodynamics also evaluate .</brief_summary>
	<brief_title>A Research Study Assess CC-930 Safe Treating Subjects With Discoid Lupus Erythematosus</brief_title>
	<detailed_description>Enrollment occur sequential , ascend , dose-sequence design , high CC-930 dose level long duration dosing ( cohort ) initiate supportive safety profile demonstrate precede cohort . There 4 cohort describe ; Cohort 1 : 25 mg daily 4 week Cohort 2 : 50 mg daily 4 week Cohort 3 : 100 mg daily 6 week Cohort 4 : 100 mg twice daily 6 week</detailed_description>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<criteria>1 . Male female clinical diagnosis Discoid Lupus Erythematosus ( DLE ) age 18 64 year 2 . Good health assess Investigator 3 . DLE least 16 week prior screen consistent histological finding . 4 . Considered candidate systemic therapy . May na√Øve systemic therapy experience incomplete refractory disease systemic therapy . 5 . Cutaneous Lupus Area Severity Index ( CLASI ) activity score least 10 , determine investigator . 6 . Subjects use hydroxychloroquine , chloroquine , quinacrine must document ophthalmologic exam within 24 week baseline visit . 7 . Must meet laboratory criterion white blood cell , absolute neutrophil , platelet , serum creatinine , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , bilirubin hemoglobin . 8 . Subjects , male female , must agree strict pregnancy prevention test requirement . 1 . Significant illness determine physician . 2 . History significant cardiac condition intervention within prior 6 month include abnormal electrocardiogram ( ECG ) finding . 3 . Systolic blood pressure &lt; 95 &gt; 150 mm Hg 4 . Diastolic blood pressure &gt; 90 mm Hg . 5 . Pregnancy breast feed . 6 . Other dermatological condition would interfere CLASI Activity Score assessment . 7 . History active ; malignancy , human immunodeficiency virus ( HIV ) , tuberculosis infection , mycobacterial infection , congenital acquire immunodeficiency , Hepatitis B C. 8 . Clinically significant abnormality chest Xray . 9 . Participation multiple CC930 cohort . 10 . History thrombolytic event . 11 . Positive test lupus anticoagulant , anticardiolipin antibody , antibody beta2 glycoprotein 1 phosphatidylserine screening . 12 . Positive antineutrophilic cytoplasmic antibody ( ANCA ) screening . 13 . Diagnosis SLE . 14 . Presence history medically significant Systemic Lupus Erythematosis ( SLE ) Lupus Erythematosis ( LE ) comorbidities . 15 . History seizure , chorea psychosis . 16 . Presence history persistent proteinuria urinary cellular cast . 17 . Prohibited prior concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Discoid Lupus</keyword>
	<keyword>DLE</keyword>
	<keyword>Cutaneous Lupus</keyword>
</DOC>